Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18 F–Fluorodeoxyglucose ( 18 F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study
作者: Christian Kelly-MorlandSarah RudmanPaul NathanSusan MallettGiovanni MontanaGary CookVicky Goh
作者单位: 1Department of Cancer Imaging, King’s College London Division of Imaging Sciences & Biomedical Engineering, St Thomas’ Hospital
2Guy’s Hospital
3Mount Vernon Cancer Centre
4University of Birmingham
5King’s College London Division of Imaging Sciences & Biomedical Engineering, St Thomas’ Hospital
刊名: BMC Cancer, 2017, Vol.17 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s12885-017-3371-9
关键词: Metastatic renal cell carcinomaMagnetic resonance imagingPositron emission tomographyPet/MRIResponse assessment
英文摘要: Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as standard size-related response criteria do not necessarily accurately reflect clinical benefit, as they may be less pronounced or occur later in therapy than devascularisation. The challenge for imaging is providing timely assessment of disease status allowing therapies to be tailored to ensure ongoing clinical benefit. We propose that combined assessment of morphological, physiological and metabolic imaging parameters using 18F–fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F–FDG PET/MRI) will better reflect disease behaviour, improving...
原始语种摘要: Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as standard size-related response criteria do not necessarily accurately reflect clinical benefit, as they may be less pronounced or occur later in therapy than devascularisation. The challenge for imaging is providing timely assessment of disease status allowing therapies to be tailored to ensure ongoing clinical benefit. We propose that combined assessment of morphological, physiological and metabolic imaging parameters using 18F–fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F–FDG PET/MRI) will better reflect disease behaviour, improving...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:3.333 (2012)

×
关键词翻译
关键词翻译
  • resonance 共振
  • imaging 图像形成
  • FDG Founding
  • positron 阳电子
  • assessment 评价
  • renal 肾的
  • tomography 断层x 线摄影
  • magnetic 磁的
  • response 响应
  • treatment 处理